Proxy Votes Now

Home › Funds › RBB FUND, INC. › F/m Emerald Life Sciences Innovation ETF

F/m Emerald Life Sciences Innovation ETF (LFSC) proxy voting record 2025-2026

Fund family: RBB FUND, INC. · Filed by RBB FUND, INC. (CIK 831114) · SEC series S000088167

Ticker: LFSC (C000254221)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 263 with, 1 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with RBB FUND, INC. as a whole

The same two figures as RBB FUND, INC.’s manager page (32,541 ballot items across 32 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsRBB FUND, INC.Items
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)78.6%25793.2%28,258
Backed environmental and social shareholder proposals at US companiesn/a011.4%324

Where this fund voted differently from most RBB FUND, INC. funds

Each ballot item this fund voted is set against the votes of the other RBB FUND, INC. funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most RBB FUND, INC. funds on 9 items (15.5% of the 58 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost RBB FUND, INC. fundsMgmtResult
GLOBUS MEDICAL, INC.2026-06-03Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders: Keith W. PfeilWithholdFOR — 3 of 3 RBB FUND, INC. fundsAgainstElected, 91.3% support
GLOBUS MEDICAL, INC.2026-06-03Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders: Robert DouglasWithholdFOR — 3 of 3 RBB FUND, INC. fundsAgainstElected, 96.9% support
AXSOME THERAPEUTICS, INC.2026-06-05Election of Director: 1. Mark SaadWithholdFOR — 3 of 4 RBB FUND, INC. fundsAgainst—
AXSOME THERAPEUTICS, INC.2026-06-05Election of Director: 2. Susan Mahony, PhD., MBAWithholdFOR — 3 of 4 RBB FUND, INC. fundsAgainst—
GUARDANT HEALTH, INC.2026-06-17Election of Class II Directors Ian ClarkWithholdFOR — 3 of 5 RBB FUND, INC. fundsAgainst—
GUARDANT HEALTH, INC.2026-06-17Election of Class II Directors Manuel Hidalgo MedinaWithholdFOR — 3 of 5 RBB FUND, INC. fundsAgainst—
BRIDGEBIO PHARMA, INC.2026-06-22Election of Director: 1. James C. MomtazeeWithholdFOR — 3 of 5 RBB FUND, INC. fundsAgainst—
BRIDGEBIO PHARMA, INC.2026-06-22Election of Director: 2. Frank P. McCormick, PhDWithholdFOR — 3 of 5 RBB FUND, INC. fundsAgainst—
BRIDGEBIO PHARMA, INC.2026-06-22Election of Director: 3. Hannah A. Valantine, MDWithholdFOR — 3 of 5 RBB FUND, INC. fundsAgainst—

Download all 9 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 97.3% of this fund’s 264 such votes could be given a sector; the other 7 (2.7%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care24910.4%
Technology800.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections1640
Audit-related370
Say-on-Pay360
Compensation170
Capital Structure90
Corporate Governance61
Other10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
SPYRE THERAPEUTICS INC.May 27, 2026$10M60
TRAVERE THERAPEUTICS, INC.May 19, 2026$8M140
GUARDANT HEALTH, INC.June 17, 2026$6M50
COGENT BIOSCIENCES, INC.June 9, 2026$6M50
MIRUM PHARMACEUTICALS, INC.June 15, 2026$5M50
UNITED THERAPEUTICS CORPORATIONJune 26, 2026$5M150
BRIDGEBIO PHARMA, INC.June 22, 2026$4M70
ICU MEDICAL, INC.May 13, 2026$4M131

Notable votes against management

MeetingCompanyProposalFundMgmt
May 13, 2026ICU MEDICAL, INC.To approve, on an advisory basis, a stockholder proposal to establish a 10% stockholder special meeting right. Shareholder proposalForAgainst

Search this fund’s votes by company

270 ballot items at 36 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, F/m Emerald Life Sciences Innovation ETF (LFSC) voted at 36 shareholder meetings of 35 companies, on 270 ballot items in all. Where management made a recommendation, the fund followed it on 99.6% of the items and voted against it 1 time. Its most frequent area of disagreement was corporate governance (1 of its votes against management). It voted on 1 shareholder proposal. It voted FOR the board's own proposals less often than RBB FUND, INC.'s funds as a whole (78.6% against 93.2%). It voted differently from most RBB FUND, INC. funds on 9 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of RBB FUND, INC.’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.